- Patient/Guest
- Phlebotomist
- Updates
| Free Light Chains | - |
|---|
|
Measure free light chains |
||
 |
Synonym | See updates |
 |
Test Code | CDBIOPR0037 |
 |
Test Type | Biochemistry |
 |
Pre-Test Condition | See updates |
 |
Report Availability | 3 D(s) |
 |
# Test(s) | Multiple |
| Test details | Sample Report |
|---|---|
| Free Light Chains |
|
|
Synonym | See updates | |
|
Test Code | CDBIOPR0037 | |
 |
Test Category | Multiple myeloma | |
|
Pre-Test Condition | See updates | |
 |
Medical History | See updates | |
|
Report Availability | 3 D(s) | |
 |
Specimen/Sample | Serum; 2 mL; SST | |
 |
Stability @21-26 deg. C | 6 Hr(s) | |
 |
Stability @ 2-8 deg. C | 7 D(s) | |
 |
Stability @ Frozen | 1 M(s) | |
|
# Test(s) | Multiple | |
 |
Processing Method | Nephelometry | |
| **Free Light Chains Kappa and Lambda LC Fr****FDA Status**: FDA-approved for plasma cell disorder testing.**Other Names**: FLC Test, Kappa/Lambda Free Light Chain Test.**Historical Breakthrough**: Developed in the 2000s to diagnose multiple myeloma, advancing hematology.**Key Purpose and Impact**: Measures free kappa and lambda light chains to diagnose or monitor multiple myeloma.**Preparation and Patient History**: Blood; report bone pain, fatigue, or paraproteinemia history.**Consent Requirement**: Standard consent for diagnostic testing.**Clinical Value**: Sensitivity ~95%; specificity ~95%; detects myeloma in ~90% of cases; guides therapy.**References Cited**: Testing.com Hematology Tests 2023; Labcorp FLC Test 2025; UpToDate Multiple Myeloma 2025 |